Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Daily News

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

L.A. McKeown

February 20, 2019

News Daily News

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

L.A. McKeown

February 19, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Industry News

Medtronic IN.PACT(TM) Admiral(TM) Drug Coated Balloon Receives FDA Approval to Treat Long SFA Lesions

April 24, 2018

Presentation VIVA 2017

Two-year Results from the IN.PACT Global Study

Presenter: Thomas Zeller

September 14, 2017

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

L.A. McKeown

September 13, 2017

News Daily News

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

L.A. McKeown

August 03, 2017

News Daily News

Drug-Coated Balloon Gets Expanded Indication for In-Stent Restenosis in PAD

Todd Neale

September 13, 2016

News Conference News ISET 2016

Drug-Coated Balloon Angioplasty Superior for In-Stent Restenosis of SFA, but Results Leave Much To Be Desired

Michael O'Riordan

February 10, 2016

News Conference News EuroPCR 2015

Studies Provide Encouraging Results for DCB in Long SFA Lesions

Caitlin E. Cox

May 22, 2015

News Daily News

Primer Estudio en Humanos ILLUMENATE: Un Nuevo Balón Recubierto de Fármacos Arroja Resultados Sólidos a los 2 Años en Lesiones de la Arteria Femoral Superficial

May 30, 2014

News Daily News

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

May 30, 2014

Advertisement

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Medtronic IN.PACT(TM) Admiral(TM) Drug Coated Balloon Receives FDA Approval to Treat Long SFA Lesions

Two-year Results from the IN.PACT Global Study

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

Drug-Coated Balloon Gets Expanded Indication for In-Stent Restenosis in PAD

Drug-Coated Balloon Angioplasty Superior for In-Stent Restenosis of SFA, but Results Leave Much To Be Desired

Studies Provide Encouraging Results for DCB in Long SFA Lesions

Primer Estudio en Humanos ILLUMENATE: Un Nuevo Balón Recubierto de Fármacos Arroja Resultados Sólidos a los 2 Años en Lesiones de la Arteria Femoral Superficial

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content